Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) (clinicaltrials.gov) - Oct 16, 2026 - P1/2 | N=59 | Completed | Sponsor: Mark Stein | Active, not recruiting ➔ Completed
Trial completion • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
|